<DOC>
	<DOCNO>NCT01188681</DOCNO>
	<brief_summary>The objective first part study determine safe dose TRU-016 use combination bendamustine patient relapse CLL . The objective second part study compare safety efficacy TRU-016 combination bendamustine bendamustine alone patient relapse CLL .</brief_summary>
	<brief_title>Safety Efficacy Study TRU-016 Plus Bendamustine vs. Bendamustine Relapsed Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This study consist two part . The initial dose escalation stage Phase 1b study evaluate safety tolerability two dose TRU-016 administered combination bendamustine patient relapse chronic lymphocytic leukemia ( CLL ) . In randomized Phase 2 stage study , efficacy safety select dose 20 mg/kg TRU-016 combine bendamustine compare bendamustine alone . The pharmacokinetics pharmacodynamics TRU-016 development antibody TRU-016 evaluate phase study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Diagnosis relapse CLL 1 3 prior treatment Demonstrated active disease require treatment No prior bendamustine treatment Not refractory fludarabine purine , either single agent combination Age &gt; /=18 year ; male female Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 Creatinine clearance &gt; 40 mL/min Absolute neutrophil count ( ANC ) &gt; /= 1,200/mm3 Platelets &gt; /= 75,000/mm3 Lymphocytes &gt; /= 5,000/mm3 Phase 1b Treatment rituximab Bcell deplete agent within 30 day alemtuzumab within 12 week Previous anticancer therapy within 30 day Refractory prior fludarabine purine analog therapy either single agent combination Receipt prior bendamustine TRU016 Receipt investigational therapy major surgery within 30 day Previous concurrent additional malignancy ( exception apply ) Any significant concurrent medical disease condition Positive serology HIV hepatitis C , hepatitis B surface antigen positive hepatitis B core antibody positive . Pregnant breast feed Drug alcohol abuse Allergic mannitol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>TRU-016</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>relapse CLL</keyword>
	<keyword>bendamustine</keyword>
</DOC>